Navigation Links
Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
Date:1/7/2008

Company to Present at 26th Annual JP Morgan Healthcare Conference

SAN DIEGO, Jan. 7 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AST-120 for the treatment of Pouchitis.

Ocera will provide an overview of the Company and an update on AST-120 at the 26th Annual JP Morgan Healthcare conference being held today, at 2:30 pm (PT) at the Westin St. Francis Hotel in San Francisco in the Elizabethan Room.

"We are pleased by the FDA's decision to grant orphan drug status for AST-120 in Pouchitis," stated Dr. Laurent Fischer, president and CEO of Ocera Therapeutics. "This designation, along with the recent positive results from the exploratory Phase 2 trial for AST-120, allows us to expand the development of AST-120 for the treatment of Pouchitis, a frequent and severe complication in patients with a J-Pouch for which there are currently no drugs approved."

Patients who suffer from ulcerative colitis often require a resection of the colon and creation of a J-Pouch to reduce the risk of cancer. A J-Pouch collects stool, but the pouch can become inflamed, resulting in a condition known as Pouchitis, which is associated with diarrhea, abdominal cramps, fever and dehydration. AST-120, an oral agent known to adsorb bile acids and bacterial toxins, as well as to mediate inflammation in the gastrointestinal tract, is currently being evaluated in a Phase 2 trial in patients with active Pouchitis.

Less than 100,000 patients in the United States suffer from Pouchitis which qualifies AST-120 for Orphan Drug status in this condition. Orphan Drug status was created by the FDA to encourage companies to develop medicines for the treatment of rare diseases by providing the developer with market exclusivity of the product for seven years, in addition to other incentives.

AST-120 was in-licensed from Kureha Corporation, Japan in 2005 and is currently being studied in a Phase 3 trial in Fistulizing Crohn's disease.

About Ocera Therapeutics, Inc.

Ocera Therapeutics, Inc. is a privately held biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera is based in San Diego and is pursuing the development of AST-120 in Crohn's disease, Pouchitis and conducting proof of concept trials in other gastrointestinal and liver diseases including, Hepatic Encephalopathy, Irritable Bowel Syndrome and Proton Pump Inhibitor-resistant Gastroesophageal Reflux Disease. Ocera Therapeutics has raised $26.5 million dollars in venture financing from Domain Associates, Sofinnova Ventures and Thomas, McNerney & Partners. Additional information on the Company can be found at http://www.oceratherapeutics.com.

For more information on Pouchitis, visit the Crohn's and Colitis Foundation of America website at http://www.ccfa.org.

Media Contact: Company Contact:

Melissa Hill Laurent Fischer

Porter Novelli Life Sciences Ocera Therapeutics, Inc.

619-849-6004 858-436-3901

mhill@pnlifesciences.com lfischer@ocerainc.com


'/>"/>
SOURCE Ocera Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. National Patient Safety Foundation Partners with Vocera Communications
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s Day tips on ... of Rama - Dr. Frederick Lenz. , According to Publisher Roger Cantu, ... teacher for teaching and helping others. Valentine’s Day celebrates love in all its ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... CITY, California (PRWEB) , ... February 12, 2016 , ... ... announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre ... healthy way to stay hydrated before the big event. The invitation-only gifting suite, held ...
(Date:2/12/2016)... ... 2016 , ... Every winter, someone is killed, injured or loses a home ... Center, part of the Allegheny Health Network, has partnered with Etna Volunteer Fire ... Need Space” campaign. , “Space Heaters Need Space” aims to bring awareness ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert ... to Know in 2016 . The list consists of physicians establishing, leading and partnering ... this list. , An Ambulatory Surgery Center, also known as an ASC, is ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
(Date:2/12/2016)... 12, 2016 Indiso ... den ungedeckten medizinischen Bedarf bei Lungen- und ... klinischen Forschungsprogramms bekannt. Das Programm, das sich ... ihrer respiratorischen Funktionen und anderer klinischer Parameter. ... Medizintechnikunternehmen, das sich auf den ungedeckten medizinischen ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... The Company also filed its Quarterly Report on Form 10-Q ... Securities and Exchange Commission today. --> ... --> --> Net sales for the ... 95%, to $5.4 million from $2.8 million for the three ...
Breaking Medicine Technology: